12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TNFalpha kinoid: Final Phase I/II data

Final data from an open-label, dose-escalation, South African and Swiss Phase I/II trial in 21 patients showed that 60 (n=3), 180 (n=9) and 360 µg (n=9) doses of intramuscular TNFalpha kinoid on days 0, 7 and 28 induced...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >